Cisplatin Ototoxicity Can Worsen Long After Treatment Ends
Cisplatin-induced ototoxicity remains one of oncology’s most durable toxicities: a permanent, bilateral sensorineural hearing loss that can affect up to 80% of treated patients. The clinical problem is not just the initial injury. Hearing can continue to deteriorate after chemotherapy stops, even when the cumulative dose no longer changes and the infusion schedule is finished. This delayed progression has made cisplatin hearing loss difficult to predict at the bedside and harder to prevent without weakening a drug that remains essential in many curative regimens.
The review brings that post-treatment trajectory into sharp focus. Rather than treating cochlear damage as a one-time event, it frames the inner ear as a site where platinum persists and continues to exert biologic pressure over time. In practical terms, that means the auditory system may keep losing reserve long after the last infusion has cleared from the bloodstream. The injury is cumulative in a broader sense than dose alone, because the cochlea appears to retain the toxic metal and remain vulnerable to its downstream effects.
A single infusion can set off a process that outlives the infusion itself.
Platinum Retention in the Cochlea Explains the Delayed Decline
The cochlea behaves differently from organs that can efficiently clear cisplatin-derived platinum. Traces of platinum have been found in human temporal bone tissue more than 18 months after the last infusion, a finding that strongly supports long-term retention rather than a purely transient exposure. Bone may function as a systemic reservoir, allowing platinum to persist and potentially redistribute over time. That reservoir concept helps explain why some patients continue to lose hearing after treatment has stopped, even when no new exposure is occurring.
Within the inner ear, platinum accumulates preferentially in the stria vascularis. This region is crucial for maintaining the endocochlear potential, the electrical gradient that enables normal hair-cell transduction. When platinum disrupts that system, outer hair cell function becomes unstable, and the cochlea loses part of its ability to amplify and fine-tune sound. The result is not a simple threshold shift alone; it is a biologic deterioration of the sensory apparatus that supports hearing fidelity.
Oxidative Stress, Mitochondrial Injury, and Synaptic Loss Drive Ongoing Damage
The review links retained platinum to a cascade of molecular injury that persists well beyond the infusion window. One major pathway involves sustained NOX3-dependent oxidative stress. Reactive oxygen species are particularly harmful in the cochlea because many inner-ear structures have limited regenerative capacity. Once oxidative stress becomes chronic, mitochondrial dysfunction follows, and energy-dependent cochlear cells lose the resilience they need to survive.
Genotoxic injury adds another layer. Non-regenerative cochlear cells are exposed to continuing damage, and that matters because the inner ear cannot readily replace those cells once they are lost. Early loss of ribbon synapses is another critical feature. These synapses connect hair cells to auditory nerve fibers, and their disruption can occur before overt cell death becomes obvious. Over time, that early synaptic injury can precipitate delayed spiral ganglion neurodegeneration, turning an initially subclinical insult into measurable and sometimes progressive hearing impairment.
The pathology is therefore not confined to one structure. It spreads across the cochlear microenvironment, linking metabolic stress, DNA injury, and neural degeneration into one prolonged toxic sequence.
Why Some Patients Are More Vulnerable Than Others
Individual susceptibility is not uniform. Pharmacogenetic variability in platinum transport and antioxidant metabolism helps explain why one patient may experience profound hearing decline while another completes treatment with less obvious injury. Transporters influence how platinum enters and leaves cochlear tissues. Antioxidant defenses influence how well cells can buffer the oxidative damage generated by the drug. Differences in either system can shift the balance between injury and tolerance.
This variability has direct clinical consequences. Audiologic toxicity cannot be understood only through age, dose, or treatment schedule. Two patients with similar exposure may follow different auditory trajectories because their inner-ear handling of platinum is not the same. That biologic diversity makes prevention more complicated, but it also points toward more precise future strategies, including risk stratification based on inherited susceptibility.
Audiologic Surveillance Needs to Outlast the Chemotherapy Course
The most actionable message from this review is the need for lifelong audiologic follow-up in patients exposed to cisplatin. Hearing loss may progress after chemotherapy has ended, so a normal or stable audiogram at treatment completion does not eliminate future risk. Repeated surveillance is necessary to detect delayed decline before communication problems become fixed and functionally disabling.
For clinicians, this means the ototoxicity conversation cannot end with the final infusion. Baseline testing, interval audiograms during treatment, and post-treatment monitoring all matter, but the review makes clear that surveillance should extend further than many routine oncology workflows currently do. This is especially relevant for patients who depend on speech discrimination for work, school, or independent living. Even modest progressive loss can alter daily function in ways that are easy to underestimate until the damage has already accumulated.
Protecting Hearing Without Undercutting Anticancer Benefit
Any protective strategy must preserve cisplatin’s antitumor activity. That constraint shapes the entire field of otoprotection. The biologic rationale is compelling: if platinum retention, oxidative stress, and synaptic injury can be interrupted without impairing cytotoxic efficacy, then hearing preservation becomes realistic rather than theoretical. The review supports that direction by tying long-term ototoxicity to defined mechanisms rather than to unavoidable fate.
Still, the review is a synthesis of mechanistic and translational research, not a randomized therapeutic trial. It clarifies why hearing loss continues, but it does not establish a single proven intervention that fully prevents the problem in all patients. The remaining challenge is to convert mechanistic insight into clinically usable protection while keeping cisplatin’s cancer-control benefits intact. Until then, the cochlea remains a tissue that can keep paying the price after the oncology visit ends.